Funded Startups in Shanghai
Across the 31 Shanghai entries shown (round dates spanning 2020-06-11 to 2025-11-24), the only disclosed round above $100M is Jade Bird Display’s $141M Ser…
Across the 31 Shanghai entries shown (round dates spanning 2020-06-11 to 2025-11-24), the only disclosed round above $100M is Jade Bird Display’s $141M Series B on 2025-11-01; the next-highest disclosed amounts are $84M (GRIT Biotechnology, 2025-10-19) and $70M (Extreme shell technology, 2025-11-24). Several capital raises also cluster tightly in November 2025, where many disclosed rounds sit between mid-November and the month’s end (e.g., Extreme shell technology on 2025-11-24; Ling Universe on 2025-11-21; TandemAI and Brise Pharma on 2025-11-15). Sector-wise, biotech is repeatedly represented (Biotechnology/Pharmaceuticals appear across multiple companies, including GRIT Biotechnology, Epigenic Therapeutics, and Brise Pharma), while stages are mixed: disclosed amounts appear at Seed, Series A, Series B, Series C, and one Series E (LEADRIVE on 2025-09-12), but a sizable share of rounds are undisclosed (17 entries).
Most recent rounds
31 shownRelated listings
Frequently asked
What stands out in deal size—does one disclosed round dwarf the rest?
Jade Bird Display’s $141M (Series B, 2025-11-01) is the only disclosed round above $100M in the list; the next-largest disclosed amounts are $84M (GRIT Biotechnology, Series C, 2025-10-19) and $70M (Extreme shell technology, Series B, 2025-11-24).
How concentrated are these rounds in time, based on the most recent entries shown?
The newest round is Extreme shell technology on 2025-11-24, and many entries fall in the same November 2025 window (for example Ling Universe on 2025-11-21 and TandemAI and Brise Pharma on 2025-11-15). The displayed range also includes two much older disclosed deals from 2020 (JW Therapeutics $100M on 2020-06-11; Harbour Biomed $103M on 2020-07-09).
Which stage labels dominate, and where are the main outliers in stage?
Disclosed funding appears across multiple stages: Seed (e.g., YanTu Marine $1M on 2025-10-30; plus others with undisclosed amounts), Series A (e.g., TandemAI $22M on 2025-11-15), Series B (e.g., Extreme shell technology $70M on 2025-11-24 and Jade Bird Display $141M on 2025-11-01), and Series C (e.g., GRIT Biotechnology $84M on 2025-10-19). LEADRIVE is the only Series E label in this view (undisclosed amount, 2025-09-12).
Are there sectors that appear repeatedly in this Shanghai list?
Biotech-adjacent categories recur across multiple companies, including GRIT Biotechnology (Biotechnology/Healthcare, $84M on 2025-10-19), Epigenic Therapeutics (Biotechnology, $60M on 2025-09-11), and Brise Pharma (Biotechnology/Pharmaceuticals, $28M on 2025-11-10). Robotics also shows up multiple times (Extreme shell technology, RoboParty, and Jingshi Technology), indicating a meaningful cluster outside pure biotech.
How much deal information is missing, and does that affect comparisons?
Out of 31 rows, 17 are labeled with undisclosed amounts (including Aiou Optics on 2025-11-20; RoboParty on 2025-11-15; and many others), limiting size-based ranking to the remaining disclosed entries. Among disclosed amounts, the smallest is YanTu Marine at $1M (Seed, 2025-10-30), which is far below the upper range anchored by Jade Bird Display’s $141M.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.